The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary artery pressure leading to right ventricular (RV) failure. While current PAH therapies improve patient outlook, they show limited benefit in attenuating RV dysfunction. Recent investigatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulvaney, Eamon P., Renzo, Fabiana, Adão, Rui, Dupre, Emilie, Bialesova, Lucia, Salvatore, Viviana, Reid, Helen M., Conceição, Glória, Grynblat, Julien, Llucià-Valldeperas, Aida, Michel, Jean-Baptiste, Brás-Silva, Carmen, Laurent, Charles E., Howard, Luke S., Montani, David, Humbert, Marc, Vonk Noordegraaf, Anton, Perros, Frédéric, Mendes-Ferreira, Pedro, Kinsella, B. Therese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794752/
https://www.ncbi.nlm.nih.gov/pubmed/36588576
http://dx.doi.org/10.3389/fcvm.2022.1063967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794752/
https://www.ncbi.nlm.nih.gov/pubmed/36588576
http://dx.doi.org/10.3389/fcvm.2022.1063967

Ejemplares similares